RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B
Keep, M. V., Hoxer, C. S., Hemstock, M., Groth, A. V., & Knight, C. (2018). A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B. Journal of Comparative Effectiveness Research, 7(1), 39-48. Advance online publication. https://doi.org/10.2217/cer-2017-0028
AIM: To develop a modeling approach to compare clinical outcomes of nonacog beta pegol to a standard-acting factor IX (FIX) product.
METHODS: Regression analysis linked FIX activity to bleed rates. Pharmacokinetic parameters were used to estimate FIX activity over time. The probability of bleeds was estimated for both treatment arms. A Markov model estimated the presence of target joints and annualized bleed rates (ABRs).
RESULTS: Higher FIX activity showed reduced ABRs (p < 0.001). Target joints resulted in higher bleed rates (p < 0.001). When FIX activity levels and bleed risks were applied to the Markov model, ABRs for nonacog beta pegol and its comparator were 2.40 and 6.36, respectively.
CONCLUSION: This model provides a starting point for assessing the added value of new FIX products.